- Home
- HY vs DNTH Comparison
HY vs DNTH Comparison
Compare HY & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HY
- DNTH
- Stock Information
- Founded
- HY 1991
- DNTH 2015
- Country
- HY United States
- DNTH United States
- Employees
- HY N/A
- DNTH N/A
- Industry
- HY Construction/Ag Equipment/Trucks
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- HY Industrials
- DNTH Health Care
- Exchange
- HY Nasdaq
- DNTH Nasdaq
- Market Cap
- HY 735.1M
- DNTH 657.0M
- IPO Year
- HY N/A
- DNTH N/A
- Fundamental
- Price
- HY $42.78
- DNTH $19.69
- Analyst Decision
- HY Strong Buy
- DNTH Strong Buy
- Analyst Count
- HY 2
- DNTH 8
- Target Price
- HY $80.00
- DNTH $53.00
- AVG Volume (30 Days)
- HY 76.7K
- DNTH 252.7K
- Earning Date
- HY 05-06-2025
- DNTH 05-12-2025
- Dividend Yield
- HY 3.36%
- DNTH N/A
- EPS Growth
- HY N/A
- DNTH N/A
- EPS
- HY 5.60
- DNTH N/A
- Revenue
- HY $4,162,100,000.00
- DNTH $6,524,000.00
- Revenue This Year
- HY N/A
- DNTH N/A
- Revenue Next Year
- HY $3.60
- DNTH N/A
- P/E Ratio
- HY $7.65
- DNTH N/A
- Revenue Growth
- HY N/A
- DNTH 102.36
- 52 Week Low
- HY $34.13
- DNTH $13.37
- 52 Week High
- HY $84.44
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- HY 58.49
- DNTH 48.42
- Support Level
- HY $37.01
- DNTH $18.43
- Resistance Level
- HY $43.72
- DNTH $21.44
- Average True Range (ATR)
- HY 1.59
- DNTH 1.44
- MACD
- HY 0.59
- DNTH -0.24
- Stochastic Oscillator
- HY 85.99
- DNTH 32.56
About HY Hyster-Yale Materials Handling Inc.
Hyster Yale Inc designs, engineers, manufactures, sells and services a comprehensive line of lift trucks, attachments, aftermarket parts and technology solutions marketed globally under the Hyster and Yale brand names. The Company has five segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni) and Nuvera Fuel Cells, LLC (Nuvera). Majority of revenue is from Lift Trucks. geographically operates in America, EMEA, JAPIC, maximum revenue from America.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.